Switch theme
Sign up to access all valuation multiples
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.
1985
9.3K+
LTM Revenue $2.4B
LTM EBITDA $554M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aspen Pharmacare has a last 12-month revenue (LTM) of $2.4B and a last 12-month EBITDA of $554M.
In the most recent fiscal year, Aspen Pharmacare achieved revenue of $2.5B and an EBITDA of $551M.
Aspen Pharmacare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aspen Pharmacare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $554M | XXX | $551M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $424M | XXX | $409M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $236M | XXX | $245M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aspen Pharmacare's stock price is ZAR 121 (or $7).
Aspen Pharmacare has current market cap of ZAR 53.8B (or $3.0B), and EV of ZAR 82.5B (or $4.6B).
See Aspen Pharmacare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $3.0B | XXX | XXX | XXX | XXX | $0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aspen Pharmacare has market cap of $3.0B and EV of $4.6B.
Aspen Pharmacare's trades at 1.9x EV/Revenue multiple, and 8.3x EV/EBITDA.
Equity research analysts estimate Aspen Pharmacare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aspen Pharmacare has a P/E ratio of 12.7x.
See valuation multiples for Aspen Pharmacare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 10.8x | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.7x | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | 59.2x | XXX | 70.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAspen Pharmacare's last 12 month revenue growth is 7%
Aspen Pharmacare's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Aspen Pharmacare's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aspen Pharmacare's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aspen Pharmacare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aspen Pharmacare acquired XXX companies to date.
Last acquisition by Aspen Pharmacare was XXXXXXXX, XXXXX XXXXX XXXXXX . Aspen Pharmacare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aspen Pharmacare founded? | Aspen Pharmacare was founded in 1985. |
| Where is Aspen Pharmacare headquartered? | Aspen Pharmacare is headquartered in South Africa. |
| How many employees does Aspen Pharmacare have? | As of today, Aspen Pharmacare has 9.3K+ employees. |
| Who is the CEO of Aspen Pharmacare? | Aspen Pharmacare's CEO is Mr. Stephen Saad. |
| Is Aspen Pharmacare publicy listed? | Yes, Aspen Pharmacare is a public company listed on JSE. |
| What is the stock symbol of Aspen Pharmacare? | Aspen Pharmacare trades under APN ticker. |
| When did Aspen Pharmacare go public? | Aspen Pharmacare went public in 1990. |
| Who are competitors of Aspen Pharmacare? | Similar companies to Aspen Pharmacare include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Aspen Pharmacare? | Aspen Pharmacare's current market cap is $3.0B |
| What is the current revenue of Aspen Pharmacare? | Aspen Pharmacare's last 12 months revenue is $2.4B. |
| What is the current revenue growth of Aspen Pharmacare? | Aspen Pharmacare revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Aspen Pharmacare? | Current revenue multiple of Aspen Pharmacare is 1.9x. |
| Is Aspen Pharmacare profitable? | Yes, Aspen Pharmacare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aspen Pharmacare? | Aspen Pharmacare's last 12 months EBITDA is $554M. |
| What is Aspen Pharmacare's EBITDA margin? | Aspen Pharmacare's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Aspen Pharmacare? | Current EBITDA multiple of Aspen Pharmacare is 8.3x. |
| What is the current FCF of Aspen Pharmacare? | Aspen Pharmacare's last 12 months FCF is $77.5M. |
| What is Aspen Pharmacare's FCF margin? | Aspen Pharmacare's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Aspen Pharmacare? | Current FCF multiple of Aspen Pharmacare is 59.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
